Bringing to market CGRP blockers, or antagonists - the most advanced of the new drugs in development for migraines - has proved challenging.
One group treated their bodies as antagonists, escalating efforts to exert control.
antagonists, the researchers explained in a footnote, 'The email to University of North Carolina students was sent from our nber.
